TY - JOUR T1 - S32212, A NOVEL 5-HT<sub>2C</sub> RECEPTOR INVERSE AGONIST/ α<sub>2</sub>-ADRENOCEPTOR ANTAGONIST AND POTENTIAL ANTIDEPRESSANT: II. A BEHAVIORAL, NEUROCHEMICAL AND ELECTROPHYSIOLOGICAL CHARACTERIZATION JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther DO - 10.1124/jpet.111.187534 SP - jpet.111.187534 AU - Anne Dekeyne AU - Mauricette Brocco AU - Florence Loiseau AU - Alain Gobert AU - Jean-Michel Rivet AU - Benjamin Di Cara AU - Thomas I. Cremers AU - Gunnar Flik AU - Kevin C.F. Fone AU - David J.G. Watson AU - Mariusz Papp AU - Trevor Sharp AU - Florence Serres AU - Raymond Cespuglio AU - Berend Olivier AU - johnny S.W. Chan AU - Gilbert Lavielle AU - Mark J. Millan Y1 - 2011/01/01 UR - http://jpet.aspetjournals.org/content/early/2011/12/16/jpet.111.187534.abstract N2 - The present studies characterized the functional profile of S32212, (N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo[e]indole-3-carboxamide), a combined serotonin (5-HT)2C receptor inverse agonist and α2-adrenoceptor antagonist that also possesses 5-HT2A antagonist properties (accompanying paper). Upon parenteral and/or oral administration, dose-dependent (0.63-40.0 mg/kg) actions were observed in diverse procedures. Both acute and sub-chronic administration of S32212 reduced immobility time in a forced swim test in rats. Acutely, it also suppressed marble-burying and aggressive behaviour in mice. Long-term administration of S32212 was associated with rapid (1 week) and sustained (5 weeks) normalization of sucrose intake in rats exposed to chronic mild stress, and with elevated levels of mRNA encoding brain-derived neurotrophic factor in hippocampus and amygdala (2 weeks). S32212 accelerated the firing rate of adrenergic perikarya in the locus coeruleus, and elevated dialysis levels of noradrenaline in frontal cortex and hippocampus of freely-moving rats. S32212 also elevated frontocortical levels of dopamine and acetylcholine whereas 5-HT, amino acids and histamine were unaffected. These neurochemical actions were paralleled by "pro-mnemonic" properties: blockade of scopolamine-induced deficits in radial maze performance and social recognition, and reversal of delay-induced impairments in social recognition, social novelty discrimination and novel object recognition. It also showed anxiolytic actions in a Vogel conflict procedure. Further, in an electroencephalographic study of sleep architecture, S32212 enhanced slow-wave and rapid-eye movement sleep, while decreasing waking. Finally, chronic administration of S32212 neither elevated body weight nor perturbed sexual behaviour in male rats. In conclusion, S32212 displays a functional profile consistent with improved mood and cognitive performance, together with satisfactory tolerance. ER -